The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review
Open accessAbstract
BACKGROUND & AIMS: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. METHODS: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for> or = 24 months. RESULTS: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p=0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p<0.001) and in 17.6% and 0% of lamivudine resistance patients with and without cirrhosis (p<0.001). HCC developed less frequently in nucleos(t)ide naive patients compared to those without virological remission (2.3% vs 7.5%, p<0.001), but there was no difference between lamivudine resistance patients with or without virological response to rescue therapy (5.9% vs 8.8%, p=0.466). CONCLUSIONS: Chronic hepatitis B patients receiving medium-term nucleos(t)ide analogue therapy had a significantly lower incidence of HCC compared to untreated patients but treatment does not completely eliminate the risk of HCC. Among the treated patients, cirrhosis, HBeAg negative at baseline and failure to remain in virological remission were associated with an increased risk of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Self-citationRising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
EASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Self-citationShafritz, D. A., Shouval, D., Sherman, H. I., Hadziyannis, S. J., & Kew, M. C. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110293051807 · Cited by 711
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lee, C.-M., Lin, S.-M., Chu, H.-C., Wu, T.-C., Yang, S.-S., Kuo, H.-S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp288 · Cited by 635
Laurent–Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., Monges, G., Thomas, G., Bioulac–Sage, P., & Zucman–Rossi, J. (2001) · Gastroenterology · doi:10.1053/gast.2001.24798 · Cited by 582
Schafer, D. F., & Sorrell, M. F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09148-x · Cited by 453
Okuda, K. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80428-6 · Cited by 443
Hepatitis B: An important public health issue
Maddrey, W. C. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200007)61:3<362::aid-jmv14>3.0.co;2-i · Cited by 390
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
SUNG, J. J. Y., TSOI, K. K. F., WONG, V. W. S., LI, K. C. T., & CHAN, H. L. Y. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03816.x · Cited by 370
Rapti, I., Dimou, E., Mitsoula, P., & Hadziyannis, S. J. (2007) · Hepatology · doi:10.1002/hep.21534 · Cited by 323
Lampertico, P., Viganò, M., Manenti, E., Iavarone, M., Sablon, E., & Colombo, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.079 · Cited by 310
Self-citationYuen, M.-F., Seto, W.-K., Chow, D. H.-F., Tsui, K., Wong, D. K.-H., Ngai, V. W.-S., Wong, B. C.-Y., Fung, J., Yuen, J. C.-H., & Lai, C.-L. (2007) · Antiviral Therapy · doi:10.1177/135965350701200816 · Cited by 257
Papatheodoridis, G. V., Manesis, E., & Hadziyannis, S. J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00094-5 · Cited by 246
Self-citationYuen, M.-F., Hui, C.-K., Cheng, C.-C., Wu, C.-H., Lai, Y.-P., & Lai, C.-L. (2001) · Hepatology · doi:10.1053/jhep.2001.25273 · Cited by 232
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200104000-00030 · Cited by 232
Lampertico, P., Del Ninno, E., Viganò, M., Romeo, R., Donato, M. F., Sablon, E., Morabito, A., & Colombo, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50148 · Cited by 215
Self-citationTherapeutic strategies in the management of patients with chronic hepatitis B virus infection
Papatheodoridis, G. V., Manolakopoulos, S., Dusheiko, G., & Archimandritis, A. J. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70264-5 · Cited by 202
Self-citationSergi, C., Adam, S., Kahl, P., & Otto, H. F. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)81188-5 · Cited by 189
Interferon-α for HBeAg-positive chronic hepatitis B
Craxı̀, A., Bona, D. D., & Cammà, C. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00154-5 · Cited by 81
Buti, M., Elefsiniotis, I. S., Jardí, R., Vargas, V., Rodríguez‐Frias, F., Schapper, M., Bonovas, S., & Esteban, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.011 · Cited by 80
Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis
Maringhini, A., Cottone, M., Sciarrino, E., et al. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01536630 · Cited by 71
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Metadata
- Authors
- Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., & Lok, A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 53
- Issue
- 2
- Pages
- 348-356
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2088305891
- Cited by
- 459
- References
- 29
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.